niacinamide has been researched along with Overweight in 4 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "NR supplementation of 1000 mg/d for 6 wk in healthy overweight or obese men and women increased skeletal muscle NAD+ metabolites, affected skeletal muscle acetylcarnitine metabolism, and induced minor changes in body composition and sleeping metabolic rate." | 5.34 | Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. ( Aarts, SABM; Auwerx, J; Connell, NJ; de Wit, VHW; Elfrink, HL; Havekes, B; Hoeks, J; Houtkooper, RH; Lindeboom, L; Lutgens, E; Mevenkamp, J; Moonen, MPB; Phielix, E; Remie, CME; Roumans, KHM; Schomakers, BV; Schrauwen, P; Schrauwen-Hinderling, VB; van de Weijer, T; Zapata-Pérez, R, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Remie, CME | 1 |
| Roumans, KHM | 1 |
| Moonen, MPB | 1 |
| Connell, NJ | 1 |
| Havekes, B | 1 |
| Mevenkamp, J | 1 |
| Lindeboom, L | 1 |
| de Wit, VHW | 1 |
| van de Weijer, T | 1 |
| Aarts, SABM | 1 |
| Lutgens, E | 1 |
| Schomakers, BV | 1 |
| Elfrink, HL | 1 |
| Zapata-Pérez, R | 1 |
| Houtkooper, RH | 1 |
| Auwerx, J | 1 |
| Hoeks, J | 1 |
| Schrauwen-Hinderling, VB | 1 |
| Phielix, E | 1 |
| Schrauwen, P | 1 |
| Hardy, RS | 1 |
| Botfield, H | 1 |
| Markey, K | 1 |
| Mitchell, JL | 1 |
| Alimajstorovic, Z | 1 |
| Westgate, CSJ | 1 |
| Sagmeister, M | 1 |
| Fairclough, RJ | 1 |
| Ottridge, RS | 1 |
| Yiangou, A | 1 |
| Storbeck, KH | 1 |
| Taylor, AE | 1 |
| Gilligan, LC | 1 |
| Arlt, W | 1 |
| Stewart, PM | 1 |
| Tomlinson, JW | 1 |
| Mollan, SP | 1 |
| Lavery, GG | 1 |
| Sinclair, AJ | 1 |
| Conze, D | 1 |
| Brenner, C | 1 |
| Kruger, CL | 1 |
| Liu, M | 1 |
| Li, L | 1 |
| Chu, J | 1 |
| Zhu, B | 1 |
| Zhang, Q | 1 |
| Yin, X | 1 |
| Jiang, W | 1 |
| Dai, G | 1 |
| Ju, W | 1 |
| Wang, Z | 1 |
| Yang, Q | 1 |
| Fang, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Nicotinamide Riboside on Metabolic Health in (Pre)Obese Humans[NCT02835664] | 15 participants (Actual) | Interventional | 2016-12-31 | Completed | |||
| Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.[NCT02017444] | Phase 2 | 31 participants (Actual) | Interventional | 2014-04-25 | Completed | ||
| NOPARK Open Label Extension Study[NCT05546567] | 400 participants (Anticipated) | Interventional | 2022-09-28 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods. (NCT02017444)
Timeframe: 16 weeks
| Intervention | AEs related to intervention (Number) |
|---|---|
| Placebo | 0 |
| AZD4017 (11b-HSD1 Inhibitor) | 9 |
The temporal change in Body Mass Index (in kg/m^2) over 12 weeks of treatment, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | kg/m^2 (Mean) |
|---|---|
| Placebo | 37.4 |
| AZD4017 (11b-HSD1 Inhibitor) | 37.5 |
The change in headache associated disability through the headache impact test-6 score (HIT 6), measured at baseline and week 12. This is scored 11-66 with higher scores indicating worse headache. (NCT02017444)
Timeframe: 12 weeks
| Intervention | Score on HIT-6 scale (Mean) |
|---|---|
| Placebo | 59.8 |
| AZD4017 (11b-HSD1 Inhibitor) | 60.1 |
ICP measured by lumbar puncture in cmCSF as the change from week 0 and week 12 of treatment, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | cmCSF (Mean) |
|---|---|
| Placebo | -0.3 |
| AZD4017 (11b-HSD1 Inhibitor) | -4.3 |
The safety and tolerability profile of AZD4017 in female patients with IIH through adverse event reporting and safety bloods. (NCT02017444)
Timeframe: 16 weeks
| Intervention | Serious adverse events (Number) |
|---|---|
| Placebo | 1 |
| AZD4017 (11b-HSD1 Inhibitor) | 0 |
The temporal change in IIH symptoms (presence or absence of diplopia, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 2 | 15 |
| Placebo | 1 | 11 |
The temporal change in IIH symptoms (presence or absence of headache, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 13 | 4 |
| Placebo | 10 | 2 |
The temporal change in IIH visual function in both eyes using a Pelli-Robson chart to evaluate log contrast sensitivity between the baseline to week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Log contrast senstivity (Mean) | |
|---|---|---|
| Baseline LCS worst eye | Week 12 LCS worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | 1.63 | 1.65 |
| Placebo | 1.63 | 1.66 |
The temporal change in OCT Total average retinal nerve fibre layer thickness (μm), measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | μm (Mean) | |
|---|---|---|
| Total average retinal nerve fibre layer baseline worst ete | Total average retinal nerve fibre layer week 12 worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | 152 | 139.7 |
| Placebo | 158.4 | 143.2 |
"The temporal change in papilloedema (evaluated at the end of trial follow up using stereoscopic fundus photographs by masked neuro-ophthalmologists to grade the images according to Frisen classification) measured at baseline and week 12. There are 6 grades, 0-5, 5 being the worst.~The modified Frisén scale for grading papilledema using fundus photography is as follows:~Grade 1 - C-Shaped halo with a temporal gap~Grade 2 - The halo becomes circumferential~Grade 3 - Loss of major vessels as they leave the disc~Grade 4 - Loss of major vessels on the disc~Grade 5 - Criteria of Grade IV + partial or total obscuration of all vessels on the disc~For further details see e.g. Scott, C.J., et al., Diagnosis and grading of papilledema in patients with raised intracranial pressure using optical coherence tomography vs clinical expert assessment using a clinical staging scale. Arch. Ophthalmol, 2010. 128(6): p. 705-711." (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Frisen grade 0 baseline | Frisen grade 0 week 12 | Frisen grade 1 baseline | Frisen grade 1 week 12 | Frisen grade 2 baseline | Frisen grade 2 week 12 | Frisen grade 3 baseline | Frisen grade 3 week 12 | Frisen grade 4 baseline | Frisen grade 4 week 12 | Frisen grade 5 baseline | Frisen grade 5 week 12 | |
| AZD4017 (11b-HSD1 Inhibitor) | 0 | 2 | 4 | 5 | 9 | 8 | 0 | 0 | 2 | 1 | 1 | 0 |
| Placebo | 0 | 0 | 2 | 2 | 5 | 6 | 3 | 3 | 1 | 1 | 0 | 0 |
The temporal change in IIH symptoms (presence or absence of tinnitus), measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 9 | 8 |
| Placebo | 7 | 5 |
The temporal change in IIH visual function in both eyes (measured by LogMAR (log of the minimum angle of resolution) chart to assess visual acuity, between the baseline to week 12, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | LogMAR (log of the minimum angle of reso (Mean) | |
|---|---|---|
| Baseline LVA worst eye | Week 12 LVA worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | 0.08 | 0.06 |
| Placebo | 0.13 | 0.09 |
The temporal change in IIH visual function in both eyes using automated perimetry (Humphrey 24-2 central threshold) to measure the visual field mean deviation between the baseline to week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Visual field mean deviation (Mean) | |
|---|---|---|
| Baseline MD worst eye | Week 12 MD worst eye | |
| AZD4017 (11b-HSD1 Inhibitor) | -6.1 | -3.4 |
| Placebo | -3.4 | -2.2 |
The temporal change in IIH symptoms (presence or absence of visual loss, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 6 | 11 |
| Placebo | 7 | 4 |
The temporal change in IIH symptoms (presence or absence of visual obscuration, measured at baseline and week 12 (NCT02017444)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Presence | Absence | |
| AZD4017 (11b-HSD1 Inhibitor) | 2 | 15 |
| Placebo | 2 | 9 |
3 trials available for niacinamide and Overweight
| Article | Year |
|---|---|
Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans.
Topics: Acetylcarnitine; Aged; Body Composition; Dietary Supplements; Female; Humans; Male; Middle Aged; Mus | 2020 |
11βHSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adolescent; Adult; Body Composition; Double-Blind Metho | 2021 |
Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults.
Topics: Administration, Oral; Adult; Dietary Supplements; Double-Blind Method; Female; Healthy Volunteers; H | 2019 |
1 other study available for niacinamide and Overweight
| Article | Year |
|---|---|
Serum N(1)-Methylnicotinamide Is Associated With Obesity and Diabetes in Chinese.
Topics: Adult; Asian People; Body Mass Index; China; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fem | 2015 |